These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 22573707)

  • 1. ▾Indacaterol for COPD.
    Drug Ther Bull; 2012 May; 50(5):58-60. PubMed ID: 22573707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of combined indacaterol and glycopyrronium bromide (QVA149) for the treatment of COPD in Japan.
    Horita N; Kaneko T
    Int J Chron Obstruct Pulmon Dis; 2015; 10():813-22. PubMed ID: 25960646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Indacaterol (Onbrez Breezhaler), oral inhalation].
    Duh D; Tanret I
    J Pharm Belg; 2011 Dec; (4):127-8. PubMed ID: 22299240
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies.
    Kerwin EM; Gotfried MH; Lawrence D; Lassen C; Kramer B
    Clin Ther; 2011 Dec; 33(12):1974-84. PubMed ID: 22177371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Indacaterol 75 μg once daily for the treatment of patients with chronic obstructive pulmonary disease: a North American perspective.
    Kerwin EM; Williams J
    Ther Adv Respir Dis; 2013 Feb; 7(1):25-37. PubMed ID: 23296242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bronchodilator efficacy and safety of indacaterol 150 μg once daily in patients with COPD: an analysis of pooled data.
    Bleecker ER; Siler T; Owen R; Kramer B
    Int J Chron Obstruct Pulmon Dis; 2011; 6():431-8. PubMed ID: 22003288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhaled indacaterol for the treatment of COPD patients with destroyed lung by tuberculosis and moderate-to-severe airflow limitation: results from the randomized INFINITY study.
    Kim CJ; Yoon HK; Park MJ; Yoo KH; Jung KS; Park JW; Lim SY; Shim JJ; Lee YC; Kim YS; Oh YM; Kim S; Yoo CG
    Int J Chron Obstruct Pulmon Dis; 2017; 12():1589-1596. PubMed ID: 28615931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Once-daily long-acting beta-agonists for chronic obstructive pulmonary disease: an indirect comparison of olodaterol and indacaterol.
    Roskell NS; Anzueto A; Hamilton A; Disse B; Becker K
    Int J Chron Obstruct Pulmon Dis; 2014; 9():813-24. PubMed ID: 25114521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of an additional dose of indacaterol in COPD patients under regular treatment with indacaterol.
    Cazzola M; Segreti A; Stirpe E; Puxeddu E; Ora J; Rogliani P; Matera MG
    Respir Med; 2013 Jan; 107(1):107-11. PubMed ID: 23083839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of long-acting bronchodilators in COPD patients according to COPD severity and ICS use.
    Decramer M; Dahl R; Kornmann O; Korn S; Lawrence D; McBryan D
    Respir Med; 2013 Feb; 107(2):223-32. PubMed ID: 23219347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination therapy with indacaterol and glycopyrronium bromide in the management of COPD: an update on the evidence for efficacy and safety.
    Ridolo E; Montagni M; Riario-Sforza GG; Baroni M; Incorvaia C
    Ther Adv Respir Dis; 2015 Apr; 9(2):49-55. PubMed ID: 25691493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Profile of inhaled glycopyrronium bromide as monotherapy and in fixed-dose combination with indacaterol maleate for the treatment of COPD.
    Prakash A; Babu KS; Morjaria JB
    Int J Chron Obstruct Pulmon Dis; 2015; 10():111-23. PubMed ID: 25609944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of indacaterol on daily physical activity in patients with untreated chronic obstructive pulmonary disease.
    Nishijima Y; Minami S; Yamamoto S; Ogata Y; Koba T; Futami S; Komuta K
    Int J Chron Obstruct Pulmon Dis; 2015; 10():439-44. PubMed ID: 25767381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monotherapy with indacaterol once daily reduces the rate of exacerbations in patients with moderate-to-severe COPD: Post-hoc pooled analysis of 6 months data from three large phase III trials.
    Wedzicha JA; Buhl R; Lawrence D; Young D
    Respir Med; 2015 Jan; 109(1):105-11. PubMed ID: 25433954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative efficacy of indacaterol in chronic obstructive pulmonary disease.
    Ribeiro M; Chapman KR
    Int J Chron Obstruct Pulmon Dis; 2012; 7():145-52. PubMed ID: 22419862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of 12-week or longer indacaterol treatment in moderate-to-severe COPD patients: a systematic review.
    Jiang FM; Liang ZA; Zheng QL; Wang RC; Luo J; Li CT
    Lung; 2013 Apr; 191(2):135-46. PubMed ID: 23306410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The safety of indacaterol for the treatment of COPD.
    Metaxas EI; Balis E
    Expert Opin Drug Saf; 2018 Jun; 17(6):637-642. PubMed ID: 29741108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Seebri Neohaler and Utibron Neohaler for COPD.
    Med Lett Drugs Ther; 2016 Mar; 58(1491):39-41. PubMed ID: 27027687
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy of indacaterol on quality of life and pulmonary function in patients with COPD and inhaler device preferences.
    Ohno T; Wada S; Hanada S; Sawaguchi H; Muraki M; Tohda Y
    Int J Chron Obstruct Pulmon Dis; 2014; 9():107-14. PubMed ID: 24489464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bronchodilator efficacy of single doses of indacaterol in Japanese patients with COPD: A randomised, double-blind, placebo-controlled trial.
    Kato M; Makita H; Uemura K; Fukuchi Y; Hosoe M; Emery C; Higgins M; Kramer B
    Allergol Int; 2010 Sep; 59(3):285-293. PubMed ID: 20567133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.